Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 377 PLANTATION STREET WORCESTER MA 01605 |
Tel: | N/A |
Website: | https://www.mustangbio.com |
IR: | See website |
Key People | ||
Michael S. Weiss Executive Chairman of the Board | Manuel Litchman President, Chief Executive Officer, Director | James B. Murphy Interim Chief Financial Officer | Peter Carney Interim Chief Accounting Officer |
Business Overview |
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition. |
Financial Overview |
For the fiscal year ended 31 December 2023, Mustang Bio Inc revenues was not reported. Net loss decreased 33% to $51.6M. Lower net loss reflects Research and development - Balancing val decrease of 34% to $38.5M (expense), General and administrative - Balancing decrease of 20% to $9.3M (expense), Stock-based Compensation in R&D decrease of 92% to $132K (expense). |
Employees: | 80 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3.53M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$48.85M as of Dec 31, 2023 |
Net annual income (TTM): | -$51.60M as of Dec 31, 2023 |
Free cash flow (TTM): | -$49.54M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 10,390,132 as of Mar 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |